$-0.67 EPS Expected for Cytokinetics, Inc. (CYTK), Last Week Attunity Ltd (ATTU) Analysts

July 11, 2017 - By Nellie Frank

Analysts expect Cytokinetics, Inc. (NASDAQ:CYTK) to report $-0.67 EPS on July, 27.They anticipate $0.38 EPS change or 131.03% from last quarter’s $-0.29 EPS. After having $-0.62 EPS previously, Cytokinetics, Inc.’s analysts see 8.06% EPS growth. About 2,353 shares traded. Cytokinetics, Inc. (NASDAQ:CYTK) has risen 88.33% since July 11, 2016 and is uptrending. It has outperformed by 71.63% the S&P500.

Among 5 analysts covering Attunity (NASDAQ:ATTU), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Attunity had 5 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Hold” rating by Craig Hallum given on Wednesday, November 2. The stock of Attunity Ltd (NASDAQ:ATTU) has “Buy” rating given on Wednesday, June 14 by Roth Capital. The stock of Attunity Ltd (NASDAQ:ATTU) has “Buy” rating given on Friday, September 11 by Ladenburg Thalmann. TH Capital maintained the shares of ATTU in report on Thursday, July 23 with “Buy” rating. See Attunity Ltd (NASDAQ:ATTU) latest ratings:

14/06/2017 Broker: Roth Capital Rating: Buy New Target: $11.0000 Maintain

About shares traded. Attunity Ltd (NASDAQ:ATTU) has declined 15.11% since July 11, 2016 and is downtrending. It has underperformed by 31.81% the S&P500.

Investors sentiment decreased to 0.56 in 2016 Q4. Its down 0.44, from 1 in 2016Q3. It turned negative, as 5 investors sold Attunity Ltd shares while 4 reduced holdings. 2 funds opened positions while 3 raised stakes. 2.61 million shares or 3.20% more from 2.53 million shares in 2016Q3 were reported. New York-based New York State Common Retirement Fund has invested 0% in Attunity Ltd (NASDAQ:ATTU). 118,000 are owned by Renaissance Technologies Lc. Prescott Gp Capital Mgmt invested in 448,870 shares. Creative Planning reported 150 shares or 0% of all its holdings. Morgan Stanley holds 0% of its portfolio in Attunity Ltd (NASDAQ:ATTU) for 3,545 shares. G2 Investment Prns Mngmt Limited Liability Company has invested 0.29% in Attunity Ltd (NASDAQ:ATTU). Deutsche Bancshares Ag stated it has 0% of its portfolio in Attunity Ltd (NASDAQ:ATTU). California Public Employees Retirement has 0% invested in Attunity Ltd (NASDAQ:ATTU). National Bank Of Ny Mellon Corporation invested in 55,717 shares or 0% of the stock. Tanaka Management invested 2.49% in Attunity Ltd (NASDAQ:ATTU). Herald Investment Mgmt Limited invested in 294,200 shares. Rice Hall James And Associate Ltd Liability Company reported 0.08% of its portfolio in Attunity Ltd (NASDAQ:ATTU).

Attunity Ltd is a provider of Big Data management software solutions that enable access, management, sharing and distribution of data across heterogeneous enterprise platforms, organizations and the cloud. The company has market cap of $124.32 million. The Company’s software solutions include data replication and distribution (Attunity Replicate, change data capture (CDC) and Attunity Gold Client Solutions), test data management (Attunity Gold Client Solutions), data connectivity (Attunity Connect), enterprise file replication (AttunityRepliWeb), managed-file-transfer (Attunity MFT), data warehouse automation (Attunity Compose), data usage analytics (Attunity Visibility) and cloud data delivery (AttunityCloudBeam). It currently has negative earnings. The Company’s software is used for projects, such as data warehousing, Hadoop, business intelligence (BI) and Big Data analytics, reporting, migration and modernization, data consolidation and distribution, and cloud initiatives.

Investors sentiment decreased to 1.08 in Q4 2016. Its down 0.08, from 1.16 in 2016Q3. It turned negative, as 8 investors sold Cytokinetics, Inc. shares while 30 reduced holdings. 17 funds opened positions while 24 raised stakes. 26.15 million shares or 1.34% less from 26.51 million shares in 2016Q3 were reported. Alliancebernstein L P has 26,500 shares for 0% of their portfolio. The Pennsylvania-based Vanguard Group has invested 0% in Cytokinetics, Inc. (NASDAQ:CYTK). Blackrock, New York-based fund reported 3,252 shares. State Street holds 0% of its portfolio in Cytokinetics, Inc. (NASDAQ:CYTK) for 897,748 shares. Fincl Bank Of Montreal Can accumulated 12,171 shares. Moreover, Susquehanna Grp Llp has 0% invested in Cytokinetics, Inc. (NASDAQ:CYTK) for 62,737 shares. Goldman Sachs Group Inc Inc reported 71,491 shares stake. Fmr Lc owns 0.01% invested in Cytokinetics, Inc. (NASDAQ:CYTK) for 5.20M shares. Blackrock Fund owns 1.63 million shares for 0% of their portfolio. California State Teachers Retirement accumulated 69,808 shares or 0% of the stock. Group One Trading Lp has invested 0% in Cytokinetics, Inc. (NASDAQ:CYTK). Sg Americas Securities Ltd Co, New York-based fund reported 15,551 shares. Leisure Capital Management has 0.12% invested in Cytokinetics, Inc. (NASDAQ:CYTK) for 11,368 shares. Blackrock Lc owns 123,763 shares for 0% of their portfolio. Blackrock Invest Ltd Liability owns 134,303 shares.

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The company has market cap of $627.91 million. The Firm is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It has a 598.71 P/E ratio. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: